Liquidia Corporation

NASDAQ:LQDA

Biotechnology

Healthcare
$56.40 +0.34%

+$0.23 today

Market cap
$5.08B
Beta
0.59
P/E (TTM)
271.8
EPS (TTM)
$0.25
52W Low $11.85High $73.22

Volume 1.22M

Average 1.50M

LQDA Debt Repayment

Cash used to repay borrowings during the period.

Liquidia CorporationNASDAQ: LQDA

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment turns negative

Q2 FY2026 debt repayment was -$8.06M, compared with $47.15M a year earlier. Trailing-twelve-month debt repayment was $29.71M. Over 3 fiscal years it compounded at +81.8% a year.

Context

  • Debt repayment amounted to 34.0% of revenue in FY2025, down 341.1 pp from a year earlier.
  • Debt repayment increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near -$8.06M or moves back toward the trailing-twelve-month quarterly average of $7.43M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$8.06M-115.0% QoQ
Last fiscal yearDec 2025
$53.82M+2.5% YoY
LTMJun 2026
$29.71M-69.5% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-117.1%——
1 year+2.5%——
3-year CAGR+81.8%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
53.82M USD
Year-over-year change
+2.5%

Debt Repayment vs competitors

How LQDA compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -69.5% is the 2nd highest of 3, against a peer median of +0.0%.
  • Debt repayment amounts to 6.6% of revenue for LQDA, versus a peer median of 0.3%.
LQDA Competitors
Debt Repayment for LQDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LQDALiquidia CorporationLTM Jun 2026$29.71M USD-69.5%+81.8%6.6%
UTHRUnited Therapeutics CorporationLTM Jun 2026$11.5M USD+102.2%—0.4%
INSMInsmed IncorporatedLTM Jun 2026$3.15M USD-102.2%—0.3%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 0 SEK——0.0%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding LQDA) —+0.0%—0.3%

Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Depreciation & Amortization5.61M3.65M2.18M2.2M1.53M
Deferred Income Tax00000
Stock-Based Compensation6.75M9.3M10.09M18.81M29.47M
Change in Working Capital(12.38M)(2.16M)5.87M(4.79M)(24.18M)
Accounts Receivables(2.99M)(2.03M)956K1.34M(51.37M)
Inventory000(241K)(22.99M)
Accounts Payables(7.56M)814K(1.15M)2.33M(2.59M)
Other Working Capital(1.83M)(945K)6.07M(8.22M)52.77M
Other Non-Cash Items566K1.64M18.8M20.76M26.42M
Operating Cash Flow(34.04M)(28.59M)(41.56M)(93.42M)(35.69M)
Capital Expenditures(107K)(592K)(1.29M)(4.95M)(4.34M)
Acquisitions (Net)05K000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(10M)(3.49M)(2M)
Investing Cash Flow(107K)(587K)(11.29M)(8.44M)(6.34M)
Debt Repayment(420K)8.96M19.37M52.5M53.82M
Common Stock Issued21.71M54.46M24.24M138.55M4.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.03M1.55M(363K)3.61M1.08M
Financing Cash Flow26.32M64.96M43.25M194.66M59.73M
Effect of Forex Changes0000(3.5M)
Net Change in Cash(7.82M)35.79M(9.6M)92.8M14.2M
Free Cash Flow(34.14M)(29.18M)(42.85M)(98.37M)(40.02M)

Liquidia Corporation

NASDAQ:LQDA

Intrinsic Alpha fair value

Locked

Current Price

$56.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.